LUCIUS Pharmaceutical announces the approval LuciAcor in Laos

Vientiane, Laos - December 30, 2025 -Lucius Pharmaceutical is focused on providing effective, safe, and reliable medications and services for patients all over the world., today announced LuciAcor (Acoramidis) have been approved by the Ministry of Health of Laos.

ATTR-CM occurs when the transthyretin (TTR) protein changes shape and forms deposits—called amyloid—that build up in the heart and other organs. Over time, these deposits stiffen the heart muscle, reduce its ability to pump blood effectively, and may lead to heart failure.

There are two main types:

• Wild-type ATTR-CM: Non-hereditary, often affecting men over 60.
• Hereditary ATTR-CM: Inherited and may show symptoms earlier in life.

With the availability of therapies for ATTR-CM, the late-onset (wild type) Transthyretin Amyloidosis can no longer be considered a rare disease.